|
NCI - HHSN268201600001C, WOMEN S HEALTH INITIATIVE - REGIONAL CENTER, MODIFICATION 3, PERIOD OF PERFORMANCE: OCTOBER 15, 2017 THRU OCTOBER 14, 2018, 8-8481398, OPTION PERIOD A2
|
268201600001C
|
$119,999
|
|
N/A
|
THE RESEARCH FOUNDATION OF STA
|
|
NCI - HHSN268201600002C, WOMEN S HEALTH INITIATIVE - REGIONAL CENTER, MODIFICATION 3, PERIOD OF PERFORMANCE: OCTOBER 15, 2017 THRU OCTOBER 14, 2018, 8-8481398, OPTION PERIOD A2
|
268201600002C
|
$114,920
|
|
N/A
|
OHIO STATE UNIV
|
|
NCI - HHSN268201600003C, WOMEN S HEALTH INITIATIVE - REGIONAL CENTER, MODIFICATION 3, PERIOD OF PERFORMANCE: OCTOBER 15, 2017 THRU OCTOBER 14, 2018, 8-8481398, OPTION PERIOD A2
|
268201600003C
|
$44,837
|
|
N/A
|
STANFORD UNIV
|
|
NCI - HHSN268201600004C, WOMEN S HEALTH INITIATIVE - REGIONAL CENTER, MODIFICATION 3, PERIOD OF PERFORMANCE: OCTOBER 15, 2017 THRU OCTOBER 14, 2018, 8-8481398, OPTION PERIOD A2
|
268201600004C
|
$95,000
|
|
N/A
|
WAKE FOREST UNIVERSITY HEALTH
|
|
NIBIB-Bioengineering and Physical Science (BEPS)
|
NEB12003-001-00135
|
$162,583
|
|
N/A
|
NIBIB-NATIONAL INSTITUTE OF BI
|
|
Best Pharmaceuticals for Children Act (BPCA)
|
NHD12014-001-01164
|
$2,351,618
|
$2,351,618
|
N/A
|
NICHD-NATIONAL INSTITUTE OF CH
|
|
Imaging Probe Development Center (IPDC)
|
NHL12016-001-01163
|
$1,529,042
|
|
N/A
|
NHLBI-NATIONAL HEART, LUNG, AN
|
|
NINDS-Mouse Imaging Facility (MIF)
|
NNS12008-001-00130
|
$281,104
|
|
N/A
|
NINDS-NATIONAL INSTITUTE OF NE
|
|
NCI - OBSSR NOD18002-001-00003
|
NOD18002-001
|
$125,000
|
$125,000
|
N/A
|
OD-OFFICE OF THE DIRECTOR
|
|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$208,000
|
N/A
|
National Institutes of Health
|
|
IGF::OT::IGF Division of Cancer Prevention, Information Technology and Informatics Support Option 1 Period of Performance 09/22/2017 - 09/21/2019
|
261201500002B
|
$3,351,670
|
|
-, -
|
INFORMATION MANAGEMENT SERVICES, INC.
|
|
Prevention of Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH)
|
261201500018I
|
$2,155,216
|
|
-, -
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Exercise Option 1 Preclinical Efficacy Evaluation of the Lipid-Based SMEDDS Formulation of DIM, BR-9001,
|
261201500042I
|
$973,931
|
|
-, -
|
IIT RESEARCH INSTITUTE
|
|
To provide comprehensive communication services for NCI, DCCPS. Base POP: 9/30/2018-9/29/2019.
|
261201700003B
|
$2,054,189
|
|
-, -
|
ICF, INC., LLC
|
|
Surveillance, Epidemiology, and End Results (SEER) Program
|
261201800002I
|
$2,780,671
|
|
-, -
|
CONNECTICUT STATE DEPT OF PUBLIC HEALTH
|
|
IGF::OT::IGF Core Infrastructure Support for Surveillance, Epidemiology, and End Results (SEER)
|
261201800004I
|
$5,002,454
|
|
-, -
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Core Infrastructure Support for Surveillance, Epidemiology, and End Results (SEER) - Health Research Institute- NYS DOH POP 5/1/18-4/30/19
|
261201800005I
|
$687,846
|
|
-, -
|
HEALTH RESEARCH INC, NEW YORK STATE DOH
|
|
SEER - Core Infrastructure
|
261201800008I
|
$530,198
|
|
-, -
|
MASSACHUSETTS STATE DEPT OF PUB HEALTH
|
|
IGF::OT::IGF Topic 378: mPROS: Mobile PRO-CTCAE Administration System for Post-Radiation Toxicities
|
261201800013C
|
$224,995
|
|
-, -
|
INTELLIGENT AUTOMATION, INC.
|
|
Programmatic Meeting
|
261201800016I
|
$1,915,502
|
|
-, -
|
UNIVERSITY OF UTAH
|
|
Regulatory Support for Cancer Prevention Agent Development
|
261201800017C
|
$2,653,402
|
|
-, -
|
CCS ASSOCIATES, INC.
|
|
IGF::OT::IGF Topic 374 Phase 1 - Topical Delivery of Nanoformulated Natural Bioactive Chemopreventive Agent in Skin Cancer. September 17, 2018 - June 16, 2019. CAN#8478358
|
261201800019C
|
$288,945
|
|
-, -
|
VASCULAR VISION PHARMACEUTICALS COMPANY
|
|
IGF::OT::IGF SBIR Topic 374, Phase I:Sustained Delivery of PARP Inhibitors for Cancer Chemoprevention
|
261201800026C
|
$300,000
|
|
-, -
|
THERANANO, LLC
|
|
Task Order #1: Centralized Chemopreventive Agent Repository and Chemistry Support
|
261201800026I
|
$3,758,949
|
|
-, -
|
MIDWEST RESEARCH INSTITUTE
|
|
Topic 375: Novel Diagnostic Imaging Modality for Monitoring Tumor Responses to a Hyperthermia Immunotherapy - Moonshot
|
261201800028C
|
$40,573
|
|
-, -
|
IMAGO SYSTEMS, INC.
|
|
Technical Information Research Resources for Cancer Preventive Agent Development
|
261201800030C
|
$2,219,906
|
|
-, -
|
CCS ASSOCIATES, INC.
|
|
DOE PNNL
|
ACN15006-001
|
$800,000
|
|
-, -
|
UNITED STATES DEPT OF ENERGY
|
|
GENETICS AND EPIGENETICS OF SUSCEPTIBILITY TO NON-ALCOHOLIC LIVER DISEASE
|
ACN18002-001
|
$80,000
|
|
-, -
|
FOOD & DRUG ADMINISTRATION
|
|
USAG UTILITIES SUPPORT FOR FNLCR
|
ACO17014-001
|
$2,609,316
|
|
-, -
|
UNITED STATES DEPARTMENT OF THE ARMY
|
|
RAEPID-18-0052
|
APC14005-003
|
$43,988
|
|
-, -
|
SOCIAL SECURITY ADMINISTRATION
|
|
SEER-MHOS REVIEW AND TECHNICAL ASSISTANCE
|
APC16004-001
|
$150,000
|
|
-, -
|
CENTERS FOR MEDICARE & MEDICAI
|
|
NCHS: NHIS CANCER CONTROL SUPPLEMENT PARTNERSHIP WITH NCI/DCCPS/HDRP
|
APC18005-001
|
$2,000,000
|
|
-, -
|
CENTERS FOR DISEASE CONTROL &
|
|
NATIONAL HEALTH AND NUTRITION EXAM SURVEY
|
APC18007-001
|
$50,000
|
|
-, -
|
CENTERS FOR DISEASE CONTROL &
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
$4,800
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
$2,400
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
$4,746
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
$7,982
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
$151,709
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Molecular mechanisms of prostate cancer metastasis
|
5R01CA183929-04
|
$366,000
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
5UM1CA186704-04
|
$1,703,461
|
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages
|
5R01CA172105-04
|
$401,456
|
|
ABRAMS, SCOTT
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Li-Fraumeni Syndrome in Brazil
|
ZIA CP010144-10769
|
$12,981
|
$2,596
|
Achatz, Maria Isabel
|
DCEG (NCI)
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$1,393,520
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-04
|
$400,000
|
$400,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
$192,024
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$22,547,116
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
$20,853,800
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Use of Bacteriophages to Prevent, Diagnose, and Treat Diseases
|
ZIA BC 010017
|
$288,207
|
|
Adhya, Sankar
|
CCR (NCI)
|
|
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
|
5UM1CA186686-04
|
$1,900,619
|
|
ADJEI, ALEX
|
MAYO CLINIC ROCHESTER
|
|
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
|
5R01CA211648-02
|
$432,788
|
|
ADLI, MAZHAR
|
UNIVERSITY OF VIRGINIA
|
Total relevant funding to Childhood Cancers for this search: $285,245,372
|